Literature DB >> 10816070

The drug cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats.

A Gschanes1, R Boado, W Sametz, M Windisch.   

Abstract

The brain-derived peptidergic drug Cerebrolysin has been found to support the survival of neurons in vitro and in vivo. In the present study, we investigated the effects of Cerebrolysin and its peptide preparation E021 on spatial learning and memory, as well as on the abundance of the blood-brain barrier GLUT1 glucose transporter (GLUT1) in 2-month-old and 24-month-old rats. Young rats were treated with the drugs or saline (2.5 ml/kg/day) daily on postnatal days 1-7, and old rats for 19 consecutive days. For behavioural testing the Morris water maze was used. The abundance of GLUT1 was determined in brain slices by immunocytochemistry. Quantification of the density of the GLUT1 immunostaining was performed using light microscopy and a computerised image analysing system. All drug-treated rats, young and old, exhibit shorter escape latencies in the water maze, on all testing days (p < 0.01), indicating improved cognitive performance. Immunohistochemical data show an age-related decrease of the density of GLUTI (p < 0.05). In young animals, the administration of the drugs led to an increase of the abundance of GLUT1 in all experimental groups (p < 0.01). In old rats, the treatment with Cerebrolysin, but not with E021, resulted in an increase in the immunoreactive GLUT1 (p < 0.01). The elevated abundance of GLUT1 after the administration of both peptidergic substances might be supportive for the cognitive effects of this drug, by causing an improved nutritional supply of glucose to the neurons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816070     DOI: 10.1023/a:1004003008683

Source DB:  PubMed          Journal:  Histochem J        ISSN: 0018-2214


  6 in total

1.  Age-related memory impairments due to reduced blood glucose responses to epinephrine.

Authors:  Ken A Morris; Qing Chang; Eric G Mohler; Paul E Gold
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

Review 2.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 3.  Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease.

Authors:  Amy R Nelson; Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Biochim Biophys Acta       Date:  2015-12-17

4.  Effects of cerebrolysin on nerve growth factor system in the aging rat brain.

Authors:  Mikhail Stepanichev; Mikhail Onufriev; Viktor Aniol; Sofia Freiman; Hemma Brandstaetter; Stefan Winter; Natalia Lazareva; Alla Guekht; Natalia Gulyaeva
Journal:  Restor Neurol Neurosci       Date:  2017       Impact factor: 2.406

5.  Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.

Authors:  X Anton Alvarez; Irene Alvarez; Antia Martinez; Iria Romero; Concha Benito; Irene Suarez; Silvia Mourente; Manuel Fantini; Jesús Figueroa; Manuel Aleixandre; Carlos Linares; Dafin Muresanu; Stefan Winter; Herbert Moessler
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 6.  Bioenergetic Impairment in the Neuro-Glia-Vascular Unit: An Emerging Physiopathology during Aging.

Authors:  Minghao Yuan; Yangyang Wang; Shengyuan Wang; Zhenting Huang; Feng Jin; Qian Zou; Jing Li; Yinshuang Pu; Zhiyou Cai
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.